In conclusion, our results provide evidence that Oct4 can induce drug-acquired chemoresistance in bladder cancer, and implicate that inhibition of Oct4 may be further explored as a therapeutic strategy to counteract acquired drug resistance. The gene discussed is POU5F1; the disease is urinary bladder carcinoma.